Compare IPAR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | TLX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 1995 | 2024 |
| Metric | IPAR | TLX |
|---|---|---|
| Price | $112.00 | $11.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $126.50 | $20.37 |
| AVG Volume (30 Days) | 168.0K | ★ 476.7K |
| Earning Date | 11-04-2026 | 10-15-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 2.34 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $1,317,700,000.00 | N/A |
| Revenue This Year | $0.03 | $15.87 |
| Revenue Next Year | $7.18 | $13.93 |
| P/E Ratio | ★ $48.31 | $150.33 |
| Revenue Growth | ★ 21.26 | N/A |
| 52 Week Low | $77.21 | $6.28 |
| 52 Week High | $129.29 | $13.11 |
| Indicator | IPAR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 48.99 |
| Support Level | $109.13 | $11.20 |
| Resistance Level | $119.40 | $11.48 |
| Average True Range (ATR) | 3.10 | 0.23 |
| MACD | -0.23 | -0.04 |
| Stochastic Oscillator | 16.08 | 47.27 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.